3800 Bridge Parkway
Suite 102
Redwood City, CA 94065
United States
650 453 0000
https://seer.bio
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 147
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Omid C. Farokhzad M.D., Ph.D. | Founder, CEO, & Chair of the Board of Directors | 1.23M | N/D | 1969 |
Ms. Elona Kogan Esq., J.D. | Chief Legal Officer,General Counsel & Secretary | 548.42k | N/D | 1969 |
Mr. Joe Laws | Chief Technology Officer and Co-Founder | N/D | N/D | N/D |
Kenny Ross | Chief Operations & Product Officer | N/D | N/D | N/D |
Ms. Marissa Dixon | Chief People Officer | N/D | N/D | N/D |
Dr. Serafim Batzoglou Ph.D. | Chief Data Officer | N/D | N/D | N/D |
Mr. Martin Goldberg Ph.D. | Senior Vice President of Development | N/D | N/D | N/D |
Dr. Asim Siddiqui Ph.D. | Senior Vice President of Research & Tech Development | N/D | N/D | N/D |
Dr. Christopher E. Mason Ph.D. | Member of Scientific Advisory Board | N/D | N/D | N/D |
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
La calificación ISS Governance QuickScore de Seer, Inc. a partir del 1 de abril de 2024 es 10. Las puntuaciones principales son Auditoría: 8; Junta: 8; Derechos del accionista: 10; Compensación: 10.